Floatz logo

Finerenone

Hyperkalemia

Hospital de Messejana Dr. Carlos Alberto Studart GomesSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Hyperkalemia cohort.

Asset / SponsorPhaseRating
Spironolactone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
Urea
University of California, San Francisco
Phase 1/2CCC

Same molecule, other indications

Finerenone is also rated in:

heart failureDormant
BB
Indicative ·
65 / 100
View asset →
diabetic kidney diseaseDormant
B
Indicative ·
62 / 100
View asset →
chronic kidney diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →